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Purpose: To review recent advances in the understanding of Graves’ ophthalmopathy (GO) 
pathogenesis as well as discuss current and future medical management strategies.
Design: Interpretive essay.
Methods: Literature review and interpretation.
Results: Medical treatment of GO has slowly evolved during the past few decades and has 
been hampered by a poor understanding of the disease at a cellular and molecular level. Current 
treatment recommendations and guidelines therefore focus on nonspecific immuno-suppression. 
Newer classes of treatment agents hold promise to more selectively target underlying cellular 
and molecular alterations in GO.
Conclusion: Cooperation between individual patients, physicians and between differing medi-
cal centers, together with a refined understanding of the pathogenesis of GO, will lead to newer 
more-effective treatments for the disease and improve patient quality of life.
Keywords: Graves’ ophthalmopathy, thyroid eye disease, thyroid-associated ophthalmopathy
Introduction
Graves’ ophthalmopathy (GO) is the most common cause of orbital disease in adults 
and develops in 25% to 50% of patients with Graves’ disease (GD).1 Although thy-
roid manifestations of GD can be effectively managed, the prevention and ultimately 
treatment of GO has remained challenging. Most patients can be managed with non-
surgical treatment, which will be the focus of this article.2 The surgical rehabilitation 
of GO has been reviewed by others.3,4 Here, we briefly review recent advances in 
the understanding of GO pathogenesis as well as discuss current and future medical 
management strategies.
Disease pathogenesis
Depending on the diagnostic criteria utilized GO can be seen in 25% to 50% of patients 
with GD. The annual incidence of GO is approximately 16 in 100,000 women and 
3 in 100,000 men.5 The clinical course of GO differs from most autoimmune disorders 
in that there is typically an active phase with remission.6 Symptoms and signs of GO 
range from periorbital pain, conjunctival injection, chemosis, photophobia, diplopia, 
grittiness, lid lag and retraction, to proptosis, ophthalmoplegia, corneal ulceration, 
optic nerve dysfunction, and vision loss. Expansion of the orbital tissue (extraocular 
muscles, connective tissue, and orbital fat) within the confines of the rigid bony orbit, 
can explain the majority of these observed findings.International Journal of General Medicine 2009:2 264
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A complex interplay between genetic and environmental 
factors contributes to susceptibility to GD. Although genetic 
predisposition to GD is well established in the literature, the 
precise role of genetic factors in the development of GO is 
unknown.7 Hereditary studies of GD have demonstrated a 
30% to 40% concordance rate for monozygotic twins, while 
dizygotic twin studies reveal a lower concordance rate of 
approximately 5%.8,9 Non-twin siblings of patients with GD also 
have been noted to have an elevated risk when compared to the 
general population.8 Numerous case-controlled studies examin-
ing the role of genetic factors in the development of both GD 
and GO have been performed. Multiple loci for GO have been 
proposed including human leucocyte antigen (HLA, 6p21⋅3), 
cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumor 
necrosis factor (TNF, 6p21⋅3), interferon-γ (12q14), intercellular 
adhesion molecule 1 (ICAM-1, 19p13), and thyroid stimulating 
hormone receptor gene (TSH-R, 14q31).7 These results have not 
been confirmed or replicated in larger studies. It may be that 
both GD and GO are clinically heterogenous disorders making 
large-scale studies difficult. The possibility that GO may be 
predominantly influenced by environmental factors, rather than 
genetic predisposition, remains.6
A unified theory to explain the pathogenesis of GO does 
not exist. GO is often (90%), but not exclusively, associated 
with the onset of Graves’ hyperthyroidism, thus suggesting a 
common autoimmune pathogenic mechanism.10 Once viewed 
as a bystander, orbital fibroblasts have been identified as a 
potential autoantibody target cell within the orbit. Thyroid-
stimulating hormone receptors (TSHr) have been identified in 
orbital fibroblasts of normal individuals and GO patients.11–13 
At the mRNA level, patients with active GO have increased 
expression of TSHr versus patients with inactive disease.14 
Furthermore, orbital fibroblasts show increased TSHr expres-
sion after adipocytic differentiation.15 Insulin-like growth 
factor-1 (IGF-1), another receptor on the orbital fibroblast 
cells, has also been shown to induce hyaluronan synthesis,16 
while thyroid-specific antigens such as thyroid peroxidase 
and thyroglobulin have been detected in orbital tissues.17,18 
Finally, autoantigens in extraocular muscles (calsequestrin) 
and orbital fibroblasts (collagen XIII) were reported to be 
specific and sensitive diagnostic markers of GO.19–21 It should 
be noted that although the autoantibody theory of GO patho-
genesis is speculative as the evidence is thus far insufficient 
to link it fully to the clinical manifestations of GO.22
Once activated, sub-populations of orbital fibroblasts 
may release cytokines, produce glycosoaminoglycans 
(GAGs), and/or increase orbital fat through adipogenesis.23 
Interleukin-6 fibroblast secretion promotes B-cell 
development and differentiation, while other chemokines 
recruit (IL-16, CXCL10, and IL-16) and activate (IL-8 
and CXCL10) T-cells.23 Activated T cells trigger cytokine 
release (INFγ, TNFα, PGD2, and 15-dPGJ2), thus potentiat-
ing further inflammation.23 One sub-population of activated 
orbital fibroblasts found predominantly in the orbital fat 
compartment termed “preadipocytes,” displays the ability 
to differentiate into mature adipocytes.24 A separate orbital 
fibroblast sub-population found in connective tissues, that 
invests the extraocular muscles, may produce GAGs such 
as hyaluronic acid. Accumulation of these GAGs within 
the body of extraocular muscles leads to edema and muscle 
swelling. These changes may be observed radiographically 
(Figure 1). Volume measurement abnormalities of orbital adi-
pose tissue and/or the extraocular muscles using computer-
ized tomography, may be detected in 87% of Graves’ patients 
with clinically detectable ophthalmopathy.25 Conceptually the 
orbit has two compartments; a fat compartment and a muscle 
compartment. It has been noted that some patients with GO 
display adipose expansion as the primary manifestation of 
their disease, while others exhibit predominantly expansion 
of the muscle component. The predominance of one sub-
population of orbital fibroblasts within the orbit may help 
to explain this observation.24
Fibroblasts also have a number of tissue-specific pheno-
types, which likely affects the selective involvement of the 
skin of the anterior lower legs, known as pretibial myxedema. 
Also termed Graves’ dermopathy, this autoimmune extrathy-
roidal manifestation of Graves’ disease is usually mild, and 
is seen in approximately 15% of patients with GO. Pretibial 
myxedema has been found to be a clinical marker of severe 
ophthalmopathy.26 Stimulation of local fibroblasts with a 
resulting production of significant amounts of GAGs, leads 
to the observed clinical manifestations.27
Figure 1 Axial CT scan of orbits, 67-year-old woman with Graves’ ophthalmopathy with 
proptosis secondary to extraocular muscle expansion.   Arrows demonstrate enlarged 
medial rectus muscles. Also note that left lateral rectus muscle is also enlarged.International Journal of General Medicine 2009:2 265
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Current medical treatment 
of Graves’ ophthalmopathy
The medical treatment of GO has gradually evolved during 
the past few decades. The relatively slow evolution of treat-
ment may be explained partly by a poor understanding of 
GO at a cellular and molecular level, as well as challenges 
of disease classification at a clinical level. This has led to 
controversy and a wide variety of medical and surgical 
recommendations.
Graves’ disease and Graves’ ophthalmopathy are chronic 
disease processes with both physical and psychological 
manifestations. Education plays an important role to help 
with understanding patient concerns along with setting and 
aligning expectations. At times, patient concerns are very 
different than physician concerns. “Clinical success” in the 
treatment of GO has been a moving target. What is defined 
as “success” in the literature may in fact have little bearing 
on patients’ perception of improvement. Current tools to 
evaluate quality of life (QOL) unfortunately lack questions 
on multiple issues that are important to most patients.28 An 
updated QOL survey will be a useful outcome measurement 
tool in future clinical trials.
Clinical grading
There is no gold standard for grading the severity or activity 
of GO. This has led to difficulty comparing treatments for 
GO due to the wide variety of models used in clinical studies. 
Examples of severity grading systems include the modified 
NOSPECS (No symptoms or signs, Only signs, Soft tis-
sue symptoms and signs, Proptosis, Extraocular muscle 
involvement, and Sight loss due to optic neuropathy) and the 
American Thyroid Association (ATA) grading systems. The 
American Thyroid Association (ATA) grading system divides 
patients according to clinical features and severity. Class 
I solely involve lid retraction or stare. Patients in Class II 
have soft tissue symptoms and signs (chemosis/edema), 
while patients in Class III have proptosis. Decreased motil-
ity and/or diplopia are characteristic of patients in Class IV . 
Finally, corneal exposure symptoms/signs or optic neuropa-
thy are found in patients with Class V and Class VI disease, 
respectively. Used to assess disease activity, the Clinical 
Activity Score (CAS) is comprised of local manifestations 
of inflammation.29 They include spontaneous retrobulbar 
pain, pain with eye movements, redness of the eyelids, 
redness of the conjunctiva, swelling of the eyelids, swell-
ing of the caruncle and/or plica, and conjunctival edema. 
A score of 3 or greater is considered active GO. The VISA 
classification system combines aspects of both the CAS 
and NOSPECS systems. Core components include Vision 
(presence of absence of optic neuropathy), Inflammation (0–8 
or mild, moderate, or severe), Strabismus/motility (0–3), and 
Appearance/exposure (mild, moderate, or severe).30
The recent release of The Consensus Statement of the 
European Group on Graves’ Orbitopathy (EUGOGO) has 
added refined recommendations to the management of GO.31 
Although the authors do not advocate a detailed clinical 
grading or scoring system, they do recommend an initial 
segregation of patients into “mild,” “moderate to severe,” 
or “sight-threatening” categories, as well as an attempt to 
determine disease activity (Table 1).
Initial management
The initial management of patients with GO flows from 
widely accepted guidelines. These include the correction of 
thyroid dysfunction, smoking cessation counseling, and local 
symptomatic treatments for corneal exposure (lubricants and 
ointments), diplopia (prisms), and photophobia (dark lenses). 
Patients with uncontrolled hyperthyroidism are more likely to 
have severe GO than euthyroid patients.31–33 Although treat-
ment modalities (thyroidectomy, antithyroid medications) 
of hyperthyroidism have similar outcomes in regards to 
GO, treatment with radioiodine has been associated with 
progression in some patients with GO or newly diagnosed 
eye disease (∼15%). This risk may be mitigated with a short 
course (3 months) of oral glucocorticoids (GCs),34 along 
with avoidance of post-operative hypothyroidism.35 Patients 
with risk factors such as smoking along with greater than 
mild GO are most likely to benefit from pretreatment. It has 
been suggested by some that only patients with preexisting 
moderate to severe GO should be pretreated with GCs.
Table 1 Severity classifications in Graves’ ophthalmopathy (GO)31
1.    Sight-threatening GO: patients with dysthyroid optic neuropathy 
(DON) and/or corneal breakdown. This category warrants immediate 
intervention.
2.    Moderate to severe GO: patients without sight-threatening GO 
whose eye disease has sufficient impact on daily life to justify the risks 
of immunosuppression (if active) or surgical intervention (if inactive). 
Patients with moderate to severe GO usually have any one or more 
of the following: lid retraction 2 mm, moderate or severe soft tis-
sue involvement, exophthalmos 3 mm above normal for race and 
gender, inconstant or constant diplopia.
3.    Mild GO: patients whose features of GO have only a minor impact 
on daily life insufficient to justify immunosuppressive or surgical 
treatment. They usually only have one or more of the following: minor 
lid retraction (2 mm), mild soft tissue involvement, exophthalmos 
3 mm above normal for race and gender, transient or no diplopia, 
corneal exposure responsive to lubricants.International Journal of General Medicine 2009:2 266
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There is a strong association between smoking and GO. 
Patients who smoke are more likely to have more severe 
GO,36,37 as well as an increased likelihood of GO progression 
after radioiodine therapy for hyperthyroidism.35 In addition, 
there appears to be a dose-related response between the 
number of cigarettes smoked per day and the probability of 
developing GO.38 Therefore, counseling to promote smoking 
cessation should take a central role in the management of all 
patients with GD. The precise mechanism underlying this 
association remains obscure, but free radical formation has 
been shown to stimulate orbital fibroblast proliferation.39
Glucocorticoids
Used for their immunosuppressive and antiinflammatory 
actions, glucocorticoids (GCs) are often utilized in the treat-
ment of active GO.31 Since the early 1950s, GCs have been 
administered through oral, local (retrobulbar or subconjunc-
tival) or intravenous routes. Retrobulbar or subconjunctival 
GC injections have been found to be less effective than oral 
GCs.40 However, this route of administration is reasonable 
when oral or intravenous GCs are contraindicated.
Oral glucocorticoids have been a mainstay in the man-
agement of GO for many years. Recent randomized clinical 
trials have compared the efficacy of oral versus intravenous 
glucocorticoids (IVGCs). A recent prospective, single-blind, 
randomized study of 70 patients, directly compared oral 
GCs (initial dose 0.1 g/day tapering 0.01 g/week) versus 
IVGCs (0.5 g, then 0.25 g, 6 weeks each) for the treatment 
of euthyroid patients with untreated, active, severe GO.43 
The authors were able to use a lower cumulative dose of 
IVGCs (4.5 g) than previous studies, and they reported a 
treatment response rate (77 vs 51%) favoring IVGCs.
A major concern of high-dose GC treatment is the risk 
of adverse side effects. Although GCs effectively suppress 
inflammation, they may be associated with a number of 
potential side effects including immunosuppression, hyper-
glycemia, osteoporosis and necrosis, together with weight 
gain. Cushing’s syndrome is an almost unavoidable side 
effect of long-term use of oral glucocorticoids. The use of 
pulse IVGCs and large cumulative doses may result in serious 
liver toxicity and even death. Reporting of fatal acute liver 
failure led some authors to recommend a cumulative dose of 
no more than 6 g.42 The European consortium recommends 
pulsed IVGCs as the treatment of choice for patients with 
moderate to severe and active GO.31 In an accompanying 
editorial, concern was raised that for some patients with 
“moderate” disease and active GO, the risk-benefit ratio for 
IVCG may be weighted toward the unacceptable risk side. 
The statement was given within the context that many 
patients will spontaneously improve, albeit not as quickly in 
the untreated group, given the natural history of the disease.44 
Monitoring of liver function, along with other potential side-
effects such as hyperglycemia and increased blood pressure, 
during and after treatment is mandatory.
Orbital radiation
Orbital radiation (OR) has been used in the treatment of GO 
for more than 90 years.45 The rationale for the use of orbital 
radiotherapy stems from its anti-inflammatory effects and the 
radiosensitivity of activated orbital T-cells and fibroblasts. 
A common cumulative dose of radiation is 20 Gy per eye, 
fractionated over a 2-week period. Known complications of 
orbital radiation are fortunately rare but may include radiation 
retinopathy and cataract,46 There are also theoretic concerns 
of cancer induction which is estimated at 0.39%.47
Orbital radiation was initially widely adopted, despite a 
lack of published data from controlled clinical trials clearly 
demonstrating its efficacy. To address this, several retrospec-
tive controlled clinical trials have been undertaken in the past 
decade. A controversial study by Gorman et al found that 
treatment with orbital radiation was no better than the natural 
history of the disease which is associated with spontaneous 
improvement.48 A recent review by Bradley et al evaluated the 
role of orbital radiation for GO by identifying 5 observational 
studies and 9 randomized controlled trials (RCTs) sufficient 
to meet inclusion criteria.49 The RCTs were qualitatively 
heterogeneous and only three of the 9 randomized trials 
were sham-controlled.48,50,51 The majority of the reviewed 
RCTs enrolled patients with moderately severe GO, although 
inclusion criteria ranged from one trial that enrolled patients 
solely with mild GO to another that enrolled patients with 
moderate to severe ophthalmopathy, including patients with 
optic neuropathy. The measured outcomes were similarly 
heterogenous and included changes in one or more clinical 
parameters such as lid fissure, proptosis, and extraocular 
muscle function, change in orbital computed tomography 
CT volume, change in NOSPECS class or grade, change in 
American Thyroid Association ophthalmopathy index, and 
change in major and minor criteria (Donaldson criteria). 
Two of the 3 sham-controlled trials demonstrated improved 
vertical range of motion in orbital radiation-treated subjects 
compared with controls.
There are a wide variety of recommendations for the use 
of orbital radiation in the treatment for GO. The European 
consortium recommends that, “Orbital irradiation (OR) 
should be considered in patients with active disease who have International Journal of General Medicine 2009:2 267
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diplopia or restricted motility.”31 Others recommend the use 
of orbital radiation as an adjunct to steroids, decompression, 
or both for recalcitrant disease.52 A larger, multicenter study 
may help to clarify some of the remaining issues surrounding 
the use of orbital radiation for GO.
Future approaches to therapy
A refined understanding of the pathogenesis of GO has led to 
the advent of new potential treatment targets (Figure 2).53,54 
In the future, it may be possible to block receptor binding 
of TRAbs or IGF-1 autoantibodies with specific monoclo-
nal anti-TSRr or anti-IGFr.10 Further downstream, orbital 
preadipocyte differentiation into mature adipocytes might 
also be inhibited.10
Inhibitors that block early steps in T and B cell activation 
have the potential to limit inflammatory cytokine and auto-
antibody production, respectively. Directed against CD20, 
which is expressed in pre-B cells and B cells, the monoclonal 
antibody rituximab (RTX) has been used in the management 
of chronic autoimmune diseases such as systemic lupus 
erythematosus, dermatomyositis, and rheumatoid arthritis 
(RA).55 RTX treatment induces necrosis and apoptosis of 
CD20+ cells. More recently, promising results have been 
reported using RTX in the treatment of GO.56,57 These initial 
studies were small but offer rationale for larger prospective, 
randomized, controlled trials.10 Other agents in this class 
include CTLA4-Ig (abatacept), a recombinant fusion protein 
that is a costimulatory or second signal-blocker of T- cell 
activation. Mimicking endogenous CTLA4, it competes with 
CD28 for B7.1 (CD80) and B7.2 (CD86) ligand binding, thus 
blocking a costimulatory signal required for optimal T cell 
activation.58,59 Abatacept was recently approved by the FDA 
for treatment of patients with RA, but to date, there are no 
published studies using the drug in patients with GO.
Anticytokine medications targeting tumor necrosis factor 
alpha (TNF-α) or IL-1 have been approved for treatment of a 
number of auto-immune diseases. In particular, anti-TNF-α 
therapies with agents, such as etanercept and infliximab, 
have been of clinical value in difficult-to-treat RA. Studies 
using these agents to treat GO are limited. Etanercept is a 
TNF-receptor/immunoglobulin fusion molecule that has 
shown some promise in treating GO in a small pilot study.60 
Infliximab, a monoclonal antibody to TNF-α, was used to 
treat a patient with sight threatening GO.61 Anakinra, an IL-1 
receptor antagonist is approved for the treatment of RA, but 
there are no reports of its use in GO.
Conclusion
A close relationship that emphasizes education and coopera-
tion between patients and physicians is crucial to the man-
agement of GO. Medical therapy for GO has evolved little 
during the past few decades and generally focuses on con-
ventional approaches of nonspecific immuno-suppression. 
This may be explained partly by a poor understanding of 
GO at a cellular and molecular level, as well as challenges 
of disease classification at a clinical level. On both fronts, 
progress is being made. Newer classes of treatment agents 
hold promise to more selectively target underlying cellular 
and molecular alterations in GO. Also, cooperation between 
multiple medical centers, as evidenced by the European 
Group on Graves’ Orbitopathy (EUGOGO) and the recent 
formation of the International Thyroid Eye Disease Study 
Group (ITEDS), have the potential to better standardize the 
language and tests used in GO.
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